Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026)
Spyre Therapeutics (SYRE) reported Income from Continuing Operations of 69005000.0 for Q1 2026, down 54.12% on a YoY basis from 150409467.16 in Q1 2025, and down 10.36% quarter-over-quarter from 62530000.0 in Q4 2025.
Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Spyre Therapeutics has reported Income from Continuing Operations for 12 years, with the latest figure at 69005000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 54.12% year-over-year to 69005000.0; the trailing twelve-month figure through Mar 2026 stood at 179435000.0 (up 14.12% YoY), and the FY2025 full-year result was 155203000.0, up 25.39% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 69005000.0, down from 62530000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 11183000.0 in Q3 2025, with the low at 217081000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 50284176.47 across 5 years, with a median of 40107000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 872.45% — and 2025, when it surged 83.8%.
- Spyre Therapeutics' Income from Continuing Operations stood at 18822000.0 in 2022, then slumped by 235.67% to 63180000.0 in 2023, then advanced by 10.9% to 56296000.0 in 2024, then decreased by 11.07% to 62530000.0 in 2025, then dropped by 10.36% to 69005000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 69005000.0 (Q1 2026), 62530000.0 (Q4 2025), and 11183000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Spyre Therapeutics | 6.35 Bn | 6.35 Bn | - | -69.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.77 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.03 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.86 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.11 Mn |
| Jun 30, 2023 | -217.08 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -22.32 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.45 Mn |
| Sep 30, 2021 | -20.31 Mn |
| Jun 30, 2021 | -6.83 Mn |